このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Exscientia マネジメント

マネジメント基準チェック /14

Exscientia'sの CEO はDave Hallettで、 Feb2023年に任命され、の在任期間は 1.33年です。は、会社の株式の0.001%を直接所有しており、その価値は€ 7.22K 。経営陣と取締役会の平均在任期間はそれぞれ1.4年と3.5年です。

主要情報

Dave Hallett

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.6yrs
CEOの所有権	0.001%
経営陣の平均在職期間	1.6yrs
取締役会の平均在任期間	3.7yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Dave Hallett (55 yo)

1.6yrs

在職期間

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Hallett	Chief Scientific Officer	1.6yrs	データなし	0.0012% £ 7.1k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.8yrs	UK£1.92m	0.038% £ 232.7k
John Overington	Chief Technology Officer	less than a year	データなし	データなし
Sara Sherman	Vice President of Investor Relations	no data	データなし	データなし
Dan Ireland	Executive VP of Legal & Company Secretary	1.7yrs	データなし	データなし
Parker Moss	Executive Vice President of Corporate Development	less than a year	データなし	データなし
Caroline Rowland	Chief People Officer	2yrs	データなし	データなし
Richard Law	Chief Business Officer	no data	データなし	データなし
Nikolaus Krall	Executive Vice President of Precision Medicine	1.7yrs	データなし	データなし
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	データなし	データなし

1.6yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: 0RKの経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
David Hallett	Chief Scientific Officer	less than a year	データなし	0.0012% £ 7.1k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.8yrs	UK£1.92m	0.038% £ 232.7k
Elizabeth Crain	Independent Non-Executive Chairman	3.6yrs	UK£282.03k	0.055% £ 334.8k
Mario Polywka	Independent Non-Executive Director	7yrs	UK£201.69k	0.045% £ 274.3k
Robert Ghenchev	Independent Non-Executive Director	4.3yrs	データなし	データなし
Franziska Michor	Independent Director	1.3yrs	UK£178.86k	0.0051% £ 31.4k

3.7yrs

平均在職期間

51yo

平均年齢

経験豊富なボード: 0RKの取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

Exscientia マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Exscientia plc, Annual General Meeting, May 18, 2022

Recent updates

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023)

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Full year 2023 earnings released: UK£1.18 loss per share (vs UK£0.97 loss in FY 2022)

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022)

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022)

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021)

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia plc to Report Q1, 2022 Results on May 25, 2022

Exscientia plc, Annual General Meeting, May 18, 2022

Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer

No independent directors

Third quarter 2021 earnings released: UK£0.059 loss per share

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14